The Khasraw Lab has some exciting news to share: three abstracts from our lab have been selected for oral presentations — and two as keynotes — at the 20th Meeting of the European Association of Neuro-Oncology (EANO 2025). EANO accepts only a small percentage of abstracts for oral presentation, so having three selected, including two keynotes, is a recognition of everyone’s hard work.
Here are the presentations:
PuMP Trial – Stage 1 Data
“Intratumoral IL-12/anti–PD-1 Oncolytic HSV1 (MVR-C5252) is safe and immunoactive in recurrent high-grade glioma: preliminary phase 1 results from a multicenter multistage clinical trial”
Session Type: Keynote
Session Title: KS01 – Can Immunotherapy Solve Glioblastoma’s Challenges? Strategies to Overcome Tumor Complexity
Tumor Infiltrating Lymphocytes
“Spatial multi-omic profiling reveals determinants of TIL expandability in high-grade gliomas”
Session Type: Keynote
Session Title: KS03 – Assembling the Brain Tumor Microenvironment
ETAPA Trial
“P30-EPS peptide vaccine is safe and immunogenic in newly diagnosed glioblastoma: a phase 1b trial”
Session Type: Oral Presentation
Session Title: OS04
Congratulations to all on this amazing accomplishment. We can’t wait to support you in October!